Another large biotech IPO has joined the calendar, seeking to buck the trend of mostly negative returns from recent listings in the industry.
U.S. Food and Drug Administration (FDA) Clears Investigational New Drug Application for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia (HeFH)
Collaboration with Eli Lilly and Company (Lilly) Expands Through Lilly’s Acquisition of Product Rights to Verve’s PCSK9 and ANGPTL3 Programs from Beam Therapeutics
Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in Patients with HeFH to be Presented at the American Heart Association (AHA) Scientific Sessions 2023 on November 12 at 3:30 p.m. ET; Company to Host Investor Event and Webcast on November 12 at 6:30 p.m. ET
Cash, Cash Equivalents and Marketable Securities of $485.2 Million with Cash Runway into 2026
On November 6, 2023, Vaccitech, a clinical-stage biopharmaceutical company, underwent a significant transformation and rebranded itself as Barinthus Biotherapeutics. This name change was a strategic move to align with the company’s new focus on developing T cell immunotherapies for chronic infectious diseases, autoimmunity, and cancer. Barinthus Biotherapeutics has shifted its primary focus from vaccine development to the creation of innovative T cell immunotherapeutic candidates.
With a vision to revolutionize immunotherapies, Barinthus Biotherapeutics is determined to utilize its advanced suite of technologies, including the ChAdOx and MVA platforms. These cutting-edge platforms have proven to induce high levels of CD8+ cytotoxic T cells and CD4+ T cells, which are crucial in enhancing the effectiveness of immunotherapies.
Effective November 7, 2023, Barinthus Biotherapeutics will trade under the new ticker symbol ‘BRNS.’ This change signifies the company’s commitment to its new direction and its dedication to advancing the field of T cell immunotherapies.
https://beststocks.com/barinthus-biotherapeutics-pioneering-t-cell-i/
Chinese President Xi Jinping is scheduled to sit down with hundreds of business leaders over dinner next week when the Asia-Pacific Economic Cooperation summit takes place in San Francisco, according to a Bloomberg report. The dinner comes amid efforts by U.S. and Chinese officials to smooth over relations, particularly as tech giants Apple Inc. (AAPL) and Qualcomm Inc. (QCOM) rely heavily on sales in China.
Zimmer Biomet Holdings Inc on Tuesday trimmed its annual revenue growth forecast due to a stronger dollar after topping analysts' estimates for third-quarter profit on robust performance in the medical device maker's knee unit.
Shares of the company fell 3.8% in morning trading after declining about 7% in October on industry-wide concerns over the impact of the soaring popularity of weight-loss drugs.
However, Zimmer played down such concerns and echoed comments from larger peers like Johnson & Johnson that the weight-loss drugs, known as GLP-1s, could help more patients become eligible for orthopedic surgeries in the longer term.
"Once the (knee) cartilage is damaged, there is no recovery...And a drop in weight is not going to cure osteoarthritis," CEO Ivan Tornos said on an earnings call.
On an adjusted basis, the company reported a profit of $1.65 per share, compared with analysts' average estimate of $1.60, according to LSEG data.
Larger peers Abbott Laboratories and Boston Scientific had also topped quarterly profit estimates on easing staffing shortages and a surge in hospital admissions for elective procedures deferred during the pandemic.
Sales at Zimmer's knees unit rose 7.5% to $706.3 million, compared to analysts' estimate of $702.9 million. That helped cushion a miss at its hips unit, where sales of $465.3 million compared with estimates of $481.7 million.
The Indiana-based company's third-quarter revenue rose 5% to $1.75 billion, in line with analysts' average estimates.
Zimmer had said earlier that it expects second- and third-quarter revenue to be a "little bit lighter" compared to the first quarter.
The hip and knee implant maker cut its full-year reported revenue forecast to a growth of 6% to 6.5% from 6.5% to 7.0% earlier while backing its full-year profit forecast of $7.47 to $7.57 per share.
https://finance.yahoo.com/news/zimmer-biomet-beats-quarterly-profit-122029348.html
Among the large-cap stocks making big moves in today’s market is drug maker BioMarin Pharmaceuticals (NASDAQ:BMRN). Shares of BMRN stock surged more than 12% in early afternoon trading today on news that Elliott Investment Management has built a stake in the company and has been working behind the scenes with management for “months,” signaling strong interest from the activist investor in this name.
Elliott Investment Management is among the more active hedge funds, often taking positions in companies that are underperforming, seeking board seats and influence to turn things around. Indeed, given BioMarin’s underperformance relative to the biotech sector this year, such a position is clearly being viewed by the market as a positive right now.
Any time a hedge fund invests more than $1 billion in a given company, it’s certainly one the market will hone in on. And given BioMarin’s market capitalization of roughly $16 billion (after today’s move), it’s clear that Elliott has some big-time skin in the game in terms of improving this company’s operations moving forward.
Initial reports noted that the exact specifics of what has been discussed between BioMarin and the hedge fund are unknown. However, it’s clear that frustration over the “slow progress in the launch of its drug Roctavian to treat hemophilia” is a factor that’s driven at least some of BioMarin’s underperformance this year. Expediting this process and improving upon the company’s execution plans can be one area in which Elliott may be able to provide support.
From a strategic and operational standpoint, some investors appear to be underwhelmed with BioMarin. The hope is that a fresh set of eyes on key problems facing the company may turn things around.
